In vitro anti-tumor immune response induced by dendritic cells transfected with hTERT recombinant adenovirus

Biochemical and Biophysical Research Communications

Volumn 351, Issue 4, 2006, Pages 927-934

  Chen, Ling ^a   Liang, Guang Ping ^a   Tang, Xu Dong ^a   Chen, Ting ^a   Cai, Yong Guo ^a   Fang, Dian Chun ^a   Yu, Song Tao ^a   Luo, Yuan Hui ^a   Yang, Shi Ming ^a  

^a SOUTHWEST HOSPITAL   (China)

Author keywords

Cytotoxic T lymphocyte (CTL); Dendritic cells; Human telomerase reverse transcriptase (hTERT); Tumor vaccine; Tumor associated antigens

Indexed keywords

COMPLEMENTARY DNA; GAMMA INTERFERON; HLA A2 ANTIGEN; TELOMERASE REVERSE TRANSCRIPTASE;

ADENOVIRUS VECTOR; ANIMAL CELL; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DNA RECOMBINATION; EFFECTOR CELL; EMBRYO; ENZYME ACTIVITY; GENE INDUCTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL LINE; TUMOR IMMUNITY; VIRAL GENE THERAPY;

ADENOVIRIDAE; ANIMALS; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; GENETIC VECTORS; HLA-A2 ANTIGEN; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON TYPE II; NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; TELOMERASE; TRANSFECTION;

ADENOVIRIDAE;

EID: 33750837242     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2006.10.165     Document Type: Article

References (33)

1. Banchereau J., and Steinman R.M. Dendritic cells and the control of immunity. Nature 392 6673 (1998) 245-252
2. Steinman R.M. Dendritic cells and immune-based therapies. Exp. Hematol. 24 8 (1997) 859-862
3. Nair S.K., Heiser A., Boczkowski D., et al. Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nature 6 (2000) 1011-1017
4. Su Z., Dannull J., Yang B.K., Dahm P., et al. Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. J. Immunol. 174 (2005) 3798-3807
5. Frankenberger B., Regn S., Geiger C., et al. Cell-based vaccines for renal carcinoma: genetically-engineered tumor cells monocyte-derived dendritic cells. World J. Urol. 23 (2005) 166-174
6. Vonderheide R.H., Domchek S.M., Schultze J.L., et al. Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. Clin. Cancer Res. 10 (2004) 828-839
7. Yee C., Thompson J.A., Byrd D., et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl. Acad. Sci. USA 99 (2002) 16168-16173
8. Carnevale-Schianca F., Cignetti A., Capaldi A., et al. Allogeneic nonmyeloablative hematopoietic cell transplantation in metastatic colon cancer: tumor-specific T cells directed to a tumor-associated antigen are generated in vivo during GVHD. Blood 107 (2006) 3795-3803
9. Cho H.I., Kim H.J., Oh S.T., et al. In vitro induction of carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes by dendritic cells transduced with recombinant adenoviruses. Vaccine 22 2 (2003) 224-236
10. Schultze J.L., Maecker B., von Bergwelt-Baildon M.S., et al. Tumour immunotherapy: new tools, new treatment modalities and new T-cell antigens. Vox Sang 80 (2001) 81-89
11. Shin J.S., Hong A., Solomon M.J., et al. The role of telomeres and telomerase in the pathology of human cancer and aging. Pathology 38 (2006) 103-113
12. Yang S.M., Fang D.C., Luo Y.H., et al. Alterations of telomerase activity and terminal restriction fragment in gastric cancer and its premalignant lesions. J. Gastroenterol Hepatol 16 (2001) 876-882
13. Shay J.W., and Bachetti S.A. survey of telomerase activity in human cancer. Eur. J. Cancer 33 (1997) 787
14. Bodnar A.G., Ouellette M., Frolkis M., et al. Extension of life-span by introduction of telomerase into normal human cells. Science 279 (1998) 349
15. Vonderheide R.H., Hahn W.C., Schultze J.L., et al. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 10 (1999) 673-679
16. Minev B., Hipp J., Firat H., et al. Cytotoxic T-cell immunity against telomerase reverse transcriptase in human. Proc. Natl. Acad. Sci. USA 97 (2000) 4796-4801
17. Nakamura M., Iwahashi M., Nakamori M., et al. Dendritic cells transduced with tumor associated antigen elicit potent therapeutic antitumor immunity: comparison with immunodominant peptied-pulsed DCs. Oncology 68 (2005) 163-170
18. Oh S.T., Kim C.H., Park M.Y., et al. Dendritic cells transduced with recombinant adenoviruses induce more efficient anti-tumor immunity than dendritic cells pulsed with peptide. Vaccine 24 15 (2006) 2860-2868
19. Landau C., Pirwitz M.J., Willard M.A., et al. Adenoviral mediated gene transfer to therosclerotic arteries after balloon angioplasty. Am. Heart J. 129 6 (1995) 1051-1057
20. Romani N., Gruner S., Brang D., et al. Proliferating dendritic cell progenitors in human blood. J. Exp. Med. 180 (1994) 83-93
21. Kraemer K., Fuessel S., Schmidt U., et al. Antisense-mediated hTERT inhibition specifically reduces the growth of human bladder cancer cells. Clin. Cancer Res. 9 (2003) 3794-3800
22. Zhang P.H., Zou L., and Tu Z.G. RNAi-hTERT inhibition hepatocellular carcinoma cell proliferation via decreasing telomerase activity. J. Surg. Res. 131 (2006) 143-149
23. Hernandez J., Garcia-Pons F., Lone Y.C., et al. Identification of a human telomerase reverse transcriptase peptide of low affinity for HLA A2.1 that induces cytotoxic T lymphocytes and mediates lysis of tumor cells. Proc. Natl. Acad. Sci. USA 99 (2002) 12275-12280
24. Vonderheide R.H., Schultze J.L., Anderson K.S., et al. Equivalent Induction of Telomerase-specific Cytotoxic T Lymphocytes from Tumor-bearing Patients and Healthy Individuals. Cancer Res. 61 (2001) 8366-8370
25. Paul L.F., Christie L., Jennifer M.A., et al. Efficacy of CD40 ligand gene therapy in malignant mesothelioma. Am. J. Respir. Cell Mol. Biol. 29 (2003) 321-330
26. Jay M.L., Ali M., Reiko Y., et al. Adenovirus vector-mediated overexpression of a truncated form of the p65 nuclear factor κB cDNA in dendritic cells enhances their function resulting in immune-mediated suppression of preexisting murine tumors. Clin. Cancer Res. 8 (2002) 3561-3569
27. Ping L., Asal A., Okada A., et al. Dramatic increase of telomerase activity during dendritic cell differentiation and mutaration. J. Leukoc. Biol. 74 (2003) 270-276
28. Diebold S.S., Cotten M., Koch N., et al. MHC class II presentation of endogenously expressed antigens by transfected dendritic cells. Gene Ther. 8 (2001) 487-493
29. Kaplan J.M., Yu Q., Piraino S.T., et al. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens. J. Immunol. 163 (1999) 699-707
30. Mack C.A., Song W.R., Carpenter H., et al. Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype. Hum Gene Ther 8 (1997) 99-109
31. Vonderheide R.H. Telomerase as a universal tumor-associated antigen for cancer immunotherapy. Oncogene 21 (2002) 674-679
32. Menzel O., Migliaccio M., Goldstein D.R., et al. Mechanisms regulating the proliferative potential of human CD8+ T lymphocytes overexpressing telomerase. J. Immunol. 177 (2006) 3657-3668
33. Vonderheide R.H., Anderson K.S., Hahn W.C., et al. Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase. Clin. Cancer Res. 7 (2001) 3343-3348